Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting

Inclusion Criteria

• •1. Patients whose data were accessible for research purposes during the study observation period.
• •2. Patients diagnosed with CML-CP at first recorded diagnosis of CML.
• •3. Patients ≥ 18 years of age at first recorded diagnosis of CML.
• •4. Patients who initiated qualifying 1L therapy for CML-CP during the study identification period. Qualifying 1L therapy treatments consisted of imatinib, dasatinib, bosutinib, or nilotinib as monotherapy.
• •5. Patients with ≥1 visit within The US Oncology Network practices following initiation of 1L therapy and through the end of the study observation period.